COMP <GO>
TCRT vs KPRX // EV/EBITDA & P/E VALUATION
Alaunos Therapeutics Inc. (NASDAQ) VS. Kiora Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: TCRT 3
— KPRX 0
■ METRIC PARITY
LAST: $1.89 (-11.27%) • MKT CAP: $7.8M
valuation
—
LAST: $1.76 (-25.42%) • MKT CAP: $7.8M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TCRT VS. KPRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TCRT | KPRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -50.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 1/9 | +2.00 | TCRT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.0 | 17.1 | +32.98 | TCRT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.8M | $7.8M | $15.9K | TCRT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TCRT REV | KPRX REV | TCRT GROSS % | KPRX GROSS % | TCRT FCF | KPRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.0K | $0 | — | — | -$3.0M | -$10.1M |
| FY 2024 | $10.0K | $16.0M | — | — | -$5.0M | $8.6M |
| FY 2023 | $5.0K | $0 | — | — | -$30.1M | -$9.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TCRT // BETA —
KPRX // BETA —